VX-272 / Vertex - LARVOL DELTA

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants (clinicaltrials.gov) - P1 | N=160 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial completion date: Mar 2027 ➔ Jun 2027 | Trial primary completion date: Mar 2027 ➔ Jun 2027

Trial completion date • Trial primary completion date • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases